Standout Papers

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lu... 2016 2026 2019 2022 1.1k
  1. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study (2016)
    Corey J. Langer, Shirish M. Gadgeel et al. The Lancet Oncology

Immediate Impact

17 from Science/Nature 55 standout
Sub-graph 1 of 18

Citing Papers

Therapy-induced senescent cancer cells contribute to cancer progression by promoting ribophorin 1-dependent PD-L1 upregulation
2025 Standout
JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
2024 StandoutScience
5 intermediate papers

Works of Harry Raftopoulos being referenced

Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non–small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study
2018
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
2016 Standout
and 1 more

Author Peers

Author Last Decade Papers Cites
Harry Raftopoulos 1518 1085 564 40 2.3k
Steven Powell 2531 1556 551 90 3.5k
Yutaka Horiguchi 705 743 769 67 2.3k
S P Balcerzak 1491 1285 275 63 2.8k
Hirohisa Yoshizawa 1710 1194 551 84 3.4k
Michel Bihl 897 897 432 58 2.5k
Eva Lieto 1685 1114 840 67 3.0k
J.H.J.M. van Krieken 1511 1312 1005 34 3.4k
Luigi Manzione 2389 1272 619 88 3.4k
Michel Marty 1806 472 564 47 3.0k
Simon Tchekmedyian 2174 1240 410 28 3.2k

All Works

Loading papers...

Rankless by CCL
2026